InnoCan Pharma Corporation
INNO
CNSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 85.69% | 164.81% | -39.13% | 26.84% | -1,092.35% |
| Total Depreciation and Amortization | 0.00% | 11.11% | 42.86% | -38.46% | 125.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -69.14% | -92.02% | 1,052.85% | -355.36% | 263.54% |
| Change in Net Operating Assets | -924.78% | 186.30% | -1,754.55% | -29.65% | 65.65% |
| Cash from Operations | -39.69% | 194.67% | 35.71% | 3.89% | 47.17% |
| Capital Expenditure | -- | 70.00% | 92.59% | 18.18% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 100.00% | -- |
| Cash from Investing | 81.25% | 66.67% | 94.12% | 43.75% | -966.67% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -20.00% | 16.67% | 16.67% | -150.00% | -225.00% |
| Issuance of Common Stock | -48.16% | -- | 196.17% | -- | 586.49% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -31.98% | -- | 442.86% | -- | -- |
| Cash from Financing | -40.68% | 16.67% | 306.16% | 56,000.00% | 1,159.13% |
| Foreign Exchange rate Adjustments | 138.30% | -708.33% | 147.37% | 172.41% | 25.40% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -120.28% | 182.96% | 182.75% | 90.54% | 149.69% |
